

SCIENTIFIC HIGHLIGHTS – IDS 2024

Practical Diabetology

- New therapies for diabetic kidney disease
- Glucose management in stroke
- Insulin - GLP1 hybrids in primary care
- SMBG in the CGM era

Lipidology

- The underuse of ezetimibe and bempedoic acid
- All about PCSK9i therapy
- Olpasiran therapy and Lipoprotein (a)
- The enigma that is icosapent ethyl

Point of View Sessions

- Is the C-peptide test coming back?
- Triple antibody test for better diagnostics
- GLP1- RA vs gliptin-gliflozin: a comparison
- Shorter acting insulins: fast, faster, fastest

Next Generation Diabetology

- Precision, fuzzy logic and the doctor's brain
- Glycemia and a fight for the cloud
- Weekly insulins. Next, a monthly therapy?
- Achieving dominion over glucagon action

Debates in Diabetes

- Type 2 diabetes remission – is it sustainable?
- CGM + MSI is better than CSII + SMBG
- Ideal treatment of early gestational diabetes
- Calories, carbs and the healthspan question

Obesity

- Will newer peptides change global obesity?
- Sarcopenic obesity in daily diabetology
- Activin - tirzepatide for fat selective weight loss
- Clinical importance of recognizing lipedema

Nutrition and Exercise

- Diet and the four horsemen
- The truth about bulletproof coffee
- When is protein intake too much?
- Meal replacement: true or fake shakes?

Clinical Pearls

- Practical approach to diabetes in pregnancy
- Diabetic "mycosis" is emerging
- Body composition in diabetes practice
- Saroglitazar, semaglutide and the fibroscan

New Ideas

- MASLD: making the name more meaningful
- Anatomy of a deprescription
- Will bariatric surgery face extinction?
- Making diabetes-specific antibiotic protocols

Experience Sharing

- Setting up a diabetes research center
- Managing Acute Charcot Foot
- CGM in people without diabetes
- Ketosis prone diabetes

